

Svenja Hardtke

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3790868/svenja-hardtke-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

1,359
citations

18
h-index

36
g-index

47
ext. papers

1,665
ext. citations

6
avg, IF

3.94
L-index

#	Paper	IF	Citations
40	Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help. <i>Blood</i> , 2005 , 106, 1924-31	2.2	235
39	Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-mediated antigen transport to the bronchial lymph node. <i>Journal of Immunology</i> , 2006 , 177, 7346-54	5.3	167
38	Cooperating mechanisms of CXCR5 and CCR7 in development and organization of secondary lymphoid organs. <i>Journal of Experimental Medicine</i> , 2003 , 197, 1199-204	16.6	156
37	Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. <i>Liver International</i> , 2013 , 33, 722-6	7.9	126
36	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , 2017 , 17, 215-222	25.5	78
35	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2019 , 19, 275-286	25.5	57
34	Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , 2017 , 65, 414-425	11.2	52
33	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , 2014 , 34, 1452-63	7.9	45
32	Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , 2018 , 38, 842-850	7.9	41
31	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019 , 70, 1008-1015	13.4	40
30	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , 2019 , 71, 301-312	13.4	34
29	Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. <i>Transplant Infectious Disease</i> , 2014 , 16, 333-9	2.7	34
28	Anti-HDV IgM as a marker of disease activity in hepatitis delta. <i>PLoS ONE</i> , 2014 , 9, e101002	3.7	31
27	Abundance of follicular helper T cells in Peyer's patches is modulated by CD155. <i>European Journal of Immunology</i> , 2009 , 39, 3160-70	6.1	26
26	Non-invasive fibrosis score for hepatitis delta. <i>Liver International</i> , 2017 , 37, 196-204	7.9	23
25	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. <i>Frontiers in Immunology</i> , 2015 , 6, 270	8.4	22
24	Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 939-945	2.2	20

23	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , 2017 , 215, 139-149	7	19
22	In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. <i>Molecular Immunology</i> , 2015 , 63, 320-7	4.3	17
21	Antigen-dependent rescue of nose-associated lymphoid tissue (NALT) development independent of LTbetaR and CXCR5 signaling. <i>European Journal of Immunology</i> , 2009 , 39, 2765-78	6.1	17
20	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1359-1368	3.4	14
19	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2020 , 73, 696-699	13.4	13
18	Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. <i>PLoS ONE</i> , 2014 , 9, e108751	3.7	13
17	MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis. <i>Hepatology</i> , 2020 , 72, 1378-1393	11.2	13
16	Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1384-1394	3.4	10
15	LBO-04-Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E-The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2019 , 70, e129-e130	13.4	9
14	Risk factors and seroprevalence of hepatitis E evaluated in frozen-serum samples (2002-2003) of pregnant women compared with female blood donors in a Southern region of Brazil. <i>Journal of Medical Virology</i> , 2018 , 90, 1856-1862	19.7	8
13	Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. <i>Liver International</i> , 2021 , 41, 295-299	7.9	8
12	Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2021 ,	7	6
11	Treatment of hepatitis Delta. <i>Clinical Liver Disease</i> , 2013 , 2, 237-239	2.2	4
10	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEx Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , 2015 , 10, e0128069	3.7	4
9	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1049-1056	2.2	4
8	Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 466-475	3.4	4
7	Current Management of HBV/HDV Coinfection and Future Perspectives. <i>Current Hepatology Reports</i> , 2015 , 14, 284-292	1	3
6	A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study. <i>Journal of Hepatology</i> , 2018 , 68, S507	13.4	2

- 5 Eradikation des Hepatitis-C-Virus und Verhinderung klinischer Endpunkte. *Gastroenterologe*, **2015**, 10, 305-309 0.1 2
- 4 A transient early HBV-DNA increase during PEG-IFN α therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. *Journal of Viral Hepatitis*, **2021**, 28, 410-419 3.4 1
- 3 Update on the Management of HBV-HDV Coinfection. *Current Hepatitis Reports*, **2012**, 11, 95-101
- 2 Hepatitis E seroprevalences in pregnant and non-pregnant women in a southern region of Brazil. *Zeitschrift Fur Gastroenterologie*, **2016**, 54, 1343-1404 1.6
- 1 Epidemiology and Natural History 403-409